| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0140-6736(97)03358-8 |
| P698 | PubMed publication ID | 9291901 |
| P2093 | author name string | F Lévi | |
| J L Misset | |||
| R Zidani | |||
| P2860 | cites work | Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin in patients with metastatic colorectal cancer | Q71778656 |
| Spontaneous or imposed circadian changes in plasma concentrations of 5-fluorouracil coadministered with folinic acid and oxaliplatin: relationship with mucosal toxicity in patients with cancer | Q72133304 | ||
| Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial | Q72732640 | ||
| Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate | Q72861536 | ||
| Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines | Q73177853 | ||
| A Multiple Testing Procedure for Clinical Trials | Q28248823 | ||
| Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer | Q35187343 | ||
| DNA cell cycle distribution and glutathione (GSH) content according to circadian stage in bone marrow of cancer patients | Q35994324 | ||
| Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma | Q38207042 | ||
| Chronotherapy for gastrointestinal cancers | Q41164147 | ||
| Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate | Q41231593 | ||
| A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer | Q41999978 | ||
| Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study | Q44664927 | ||
| Factors influencing the natural history of colorectal liver metastases | Q44996217 | ||
| Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases. | Q51129985 | ||
| Impact of protracted venous infusion fluorouracil with or without interferon alfa-2b on tumor response, survival, and quality of life in advanced colorectal cancer. | Q53639104 | ||
| Quality of life during chemotherapy in patients with symptomatic advanced colorectal cancer. The Nordic Gastrointestinal Tumor Adjuvant Therapy Group. | Q54268717 | ||
| Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project | Q68056139 | ||
| Phase III study of bolus versus infusion fluorouracil with or without cisplatin in advanced colorectal cancer | Q71072643 | ||
| Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy | Q71656886 | ||
| P433 | issue | 9079 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | fluorouracil | Q238512 |
| oxaliplatin | Q422327 | ||
| multicenter clinical trial | Q6934595 | ||
| colorectal cancer | Q188874 | ||
| P304 | page(s) | 681-686 | |
| P577 | publication date | 1997-09-01 | |
| P1433 | published in | The Lancet | Q939416 |
| P1476 | title | Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy | |
| P478 | volume | 350 |
| Q33925505 | 5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development |
| Q61868238 | A clinical nomogram for predicting long-term survival in advanced colorectal cancer |
| Q35648608 | A computational model for functional mapping of genes that regulate intra-cellular circadian rhythms |
| Q42580401 | A dynamic model for functional mapping of biological rhythms |
| Q85037375 | A multicenter phase II clinical study of oxaliplatin, folinic acid, and 5-fluorouracil combination chemotherapy as first-line treatment for advanced colorectal cancer: a Japanese experience |
| Q33357544 | A phase II study of irinotecan plus chronomodulated oxaliplatin, 5-fluorouracil and folinic acid in advanced colorectal cancer patients |
| Q33390957 | A phase II trial and pharmacokinetic study of oxaliplatin in children with refractory solid tumors: a Children's Oncology Group study |
| Q33746097 | A review of the pharmacology and clinical activity of new chemotherapy agents for the treatment of colorectal cancer |
| Q51062307 | A robustness-based approach to systems-oriented drug design. |
| Q33209415 | A two-stage hepatectomy procedure combined with portal vein embolization to achieve curative resection for initially unresectable multiple and bilobar colorectal liver metastases |
| Q89014670 | About time |
| Q21245616 | An integrated psychological strategy for advanced colorectal cancer patients |
| Q33919546 | Basis for effective combination cancer chemotherapy with antimetabolites |
| Q28200468 | Biologic clocks and the gut |
| Q35030286 | Cancer chronotherapy: principles, applications, and perspectives |
| Q43885260 | Capecitabine and oxaliplatin in advanced colorectal cancer: a dose-finding study. |
| Q44265021 | Cell kinetics-dependent antitumor effect of irinotecan hydrochloride induced by the synchronizing effect of hydroxyurea: cell kinetics and dosing time |
| Q26827240 | Cetuximab therapy in the treatment of metastatic colorectal cancer: the future frontier? |
| Q44635090 | Changes in toxicity and effectiveness with timing of drug administration: implications for drug safety |
| Q34087232 | Chemotherapy-induced oral mucositis. Prevention and management |
| Q24239845 | Chronomodulated chemotherapy versus conventional chemotherapy for Advanced and /or Metastatic Colorectal Cancer |
| Q30914834 | Chronomodulated chemotherapy versus conventional chemotherapy for advanced colorectal cancer: a meta-analysis of five randomized controlled trials. |
| Q77306648 | Chronopharmacokinetics. Current status |
| Q73526632 | Chronotherapy with 5-fluorouracil, folinic acid and carboplatin for metastatic colorectal cancer; an interesting therapeutic index in a phase II trial |
| Q73846648 | Chronotherapy with 5-fluorouracil, oxaliplatin, and folinic acid in colorectal cancer |
| Q100472612 | Circadian Variation in Efficacy of Medications |
| Q34572050 | Circadian chronotherapy for human cancers |
| Q35842142 | Circadian expression of clock genes in human oral mucosa and skin: association with specific cell-cycle phases |
| Q36623730 | Circadian optimisation of irinotecan and oxaliplatin efficacy in mice with Glasgow osteosarcoma. |
| Q98471395 | Circadian regulation of chemotherapy-induced peripheral neuropathic pain and the underlying transcriptomic landscape |
| Q87258908 | Circadian rhythm of homocysteine is hCLOCK genotype dependent |
| Q44970757 | Circadian rhythms in endocrinology |
| Q92383546 | Circadian rhythms: a regulator of gastrointestinal health and dysfunction |
| Q40649814 | Circadian telomerase activity and DNA synthesis for timing peptide administration |
| Q43517192 | Circadian variation in O6-alkylguanine-DNA alkyltransferase activity in circulating blood mononuclear cells of healthy human subjects |
| Q35108451 | Circadian variation in plasma 5-fluorouracil concentrations during a 24 hour constant-rate infusion |
| Q41982816 | Circadian variation in the expression of cell-cycle proteins in human oral epithelium |
| Q58371727 | Circulating tumoral cells lack circadian-rhythm in hospitalized metastasic breast cancer patients |
| Q39806365 | Cisplatin-induced apoptosis in rat dorsal root ganglion neurons is associated with attempted entry into the cell cycle |
| Q34711514 | Clinical and economic benefits of irinotecan in combination with 5-fluorouracil and folinic acid as first line treatment of metastatic colorectal cancer |
| Q46881439 | Clinical pharmacokinetics of oxaliplatin and 5-fluorouracil administered in combination with leucovorin in Korean patients with advanced colorectal cancer. |
| Q80311367 | Colorectal cancer with non-resectable synchronous metastases: should the primary tumor be resected? |
| Q35206803 | Colorectal cancer: integrating oxaliplatin |
| Q93911723 | Colorectal cancer: treatment of advanced disease |
| Q40415873 | Combining systemic chemotherapy with chemoembolization in the treatment of unresectable hepatic metastases from colorectal cancer |
| Q33582645 | Comparison of acute skin reaction following morning versus late afternoon radiotherapy in patients with breast cancer who have undergone curative surgical resection. |
| Q92086522 | Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway |
| Q30438418 | Daily timed meals dissociate circadian rhythms in hepatoma and healthy host liver |
| Q28512318 | Dihydropyrimidine dehydrogenase circadian rhythm in mouse liver: comparison between enzyme activity and gene expression |
| Q34427755 | Disease management considerations: disease management considerations |
| Q36504713 | Diurnal variation in probability of death following self-poisoning in Sri Lanka--evidence for chronotoxicity in humans |
| Q42166589 | Dosing time dependency of doxorubicin-induced cardiotoxicity and bone marrow toxicity in rats |
| Q86481857 | Drug-induced steatohepatitis |
| Q40543641 | Effects of oxaliplatin and CPT-11 on cytotoxicity and nucleic acid incorporation of the fluoropyrimidines |
| Q35581170 | Emerging drugs in colorectal cancer |
| Q49923401 | Exploiting Metabolic Vulnerabilities of Cancer with Precision and Accuracy. |
| Q54028703 | Factors predicting for efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU)+/-folinic acid (FA) in a compassionate-use cohort of 370 5-FU-resistant advanced colorectal cancer (CRC) patients. |
| Q35629061 | First-line treatment strategies to improve survival in patients with advanced colorectal cancer |
| Q34606456 | From circadian rhythms to cancer chronotherapeutics |
| Q35123019 | Hepatic resection after down-staging of unresectable hepatic colorectal metastases |
| Q44943214 | High-dose chronomodulated infusion of 5-fluorouracil (5-FU) and folinic acid (FA) (FF5-16) in advanced colorectal cancer patients |
| Q33337184 | High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7). |
| Q39173573 | Hobson's choice two-stage hepatectomy for multiple and bilobar colorectal liver metastases with portal vein embolization: report of two cases |
| Q36486034 | How may anticancer chemotherapy with fluorouracil be individualised? |
| Q28388632 | Human blood metabolite timetable indicates internal body time |
| Q24809575 | Human molecular chronotyping in sight? |
| Q39030709 | Hydrogel-nanoparticle composites for optically modulated cancer therapeutic delivery |
| Q34155719 | Hypersensitivity Reactions Associated with Platinum Antineoplastic Agents: A Systematic Review |
| Q36671350 | Hypersensitivity reactions related to oxaliplatin (OHP). |
| Q30487471 | Imaging multidimensional therapeutically relevant circadian relationships |
| Q73880865 | Immunohemolytic anemia following oxaliplatin administration |
| Q55330048 | Impact of body weight, low energy diet and gastric bypass on drug bioavailability, cardiovascular risk factors and metabolic biomarkers: protocol for an open, non-randomised, three-armed single centre study (COCKTAIL). |
| Q43207027 | Impaired light detection of the circadian clock in a zebrafish melanoma model. |
| Q37708889 | Increased hepatic FDG uptake on PET/CT in hepatic sinusoidal obstructive syndrome. |
| Q39932516 | Influence of chemotherapy on liver regeneration induced by portal vein embolization or first hepatectomy of a staged procedure for colorectal liver metastases |
| Q36146524 | Influence of dosing times on cisplatin-induced peripheral neuropathy in rats |
| Q92675538 | Interplay between Circadian Clock and Cancer: New Frontiers for Cancer Treatment |
| Q24235217 | Interventions for preventing oral mucositis for patients with cancer receiving treatment |
| Q24235482 | Interventions for preventing oral mucositis for patients with cancer receiving treatment |
| Q24243046 | Interventions for preventing oral mucositis for patients with cancer receiving treatment |
| Q24246310 | Interventions for preventing oral mucositis for patients with cancer receiving treatment |
| Q73515956 | Investigation of the comparative toxicity of 5-FU bolus versus 5-FU continuous infusion circadian chemotherapy with concurrent radiation therapy in locally advanced rectal cancer |
| Q33706287 | Is there a standard chemotherapeutic strategy in colorectal cancer? |
| Q53299729 | It is time for chronotherapy! |
| Q53317449 | It's time for chronotherapy! |
| Q80215680 | Liver resection for primarily unresectable colorectal metastases downsized by chemotherapy |
| Q35666090 | Management of colorectal cancer in elderly patients: focus on the cost of chemotherapy |
| Q37209677 | Measurement of internal body time by blood metabolomics. |
| Q92477478 | Medicine in the Fourth Dimension |
| Q59064387 | Medicine’s secret ingredient — it’s in the timing |
| Q47162410 | Molecular Aspects of Circadian Pharmacology and Relevance for Cancer Chronotherapy |
| Q37388348 | Molecular-timetable methods for detection of body time and rhythm disorders from single-time-point genome-wide expression profiles |
| Q43873489 | N-(phosphonacetyl)-L-aspartate and calcium leucovorin modulation of fluorouracil administered by constant rate and circadian pattern of infusion over 72 hours in metastatic gastrointestinal adenocarcinoma |
| Q78111169 | Neoadjuvant chemotherapy for unresectable liver metastases of colorectal cancer--too good to be true? |
| Q33875868 | New directions in the treatment of colorectal cancer: a look to the future |
| Q40845274 | New drugs in the treatment of colorectal carcinoma |
| Q35741932 | New systemic frontline treatment for metastatic colorectal carcinoma |
| Q44767634 | Nordic 5-fluorouracil/leucovorin bolus schedule combined with oxaliplatin (Nordic FLOX) as first-line treatment of metastatic colorectal cancer |
| Q91783635 | Outcomes of staged hepatectomies for liver malignancy |
| Q33331373 | Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR. |
| Q28364999 | Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer |
| Q33998344 | Oxaliplatin clinical activity: a review |
| Q46466480 | Oxaliplatin neurotoxicity: a report of three cases with post-operative exacerbation |
| Q34086049 | Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies |
| Q37449141 | Oxaliplatin/5-FU without leucovorin chemotherapy in metastatic colorectal cancer |
| Q80473371 | Oxaliplatin/fluorouracil/leucovorin (FOLFOX4 and modified FOLFOX6) in patients with refractory or advanced colorectal cancer: post-approval Japanese population experience |
| Q31935266 | Oxaliplatin: a new agent for colorectal cancer |
| Q34569008 | Oxaliplatin: a review of evolving concepts |
| Q35214568 | Oxaliplatin: a review of its use in combination therapy for advanced metastatic colorectal cancer |
| Q33688811 | Oxaliplatin: a review of its use in the management of metastatic colorectal cancer |
| Q54114691 | Oxaliplatin: a review of preclinical and clinical studies. |
| Q33834597 | Oxaliplatin: pharmacokinetics and chronopharmacological aspects |
| Q34979779 | Oxaliplatin: results in colorectal carcinoma. |
| Q35111182 | Palliative Treatment of Patients with Colorectal Cancer |
| Q34558173 | Palliative and adjuvant chemotherapy in colorectal cancer |
| Q33179720 | Period shift induction by intermittent stimulation in a Drosophila model of PER protein oscillations. |
| Q43965431 | Pharmaco-economic comparative evaluation of combination chronotherapy vs. standard chemotherapy for colorectal cancer |
| Q44663671 | Pharmacokinetic study of oxaliplatin iv chronomodulated infusion combined with 5-fluorouracil iv continuous infusion in the treatment of advanced colorectal cancer |
| Q44268701 | Pharmacological blockage of serotonin biosynthesis and circadian changes in oxaliplatin toxicity in rats |
| Q94555685 | Phase I pharmacological study of continuous chronomodulated capecitabine treatment |
| Q33811941 | Platinum neurotoxicity: clinical profiles, experimental models and neuroprotective approaches |
| Q85001765 | Postchemotherapy histological analysis of major intrahepatic vessels for reversal of attachment or invasion by colorectal liver metastases |
| Q36616830 | Preclinical relevance of dosing time for the therapeutic index of gemcitabine-cisplatin |
| Q92726617 | Predictability of individual circadian phase during daily routine for medical applications of circadian clocks |
| Q37187386 | Predictive factors for chemotherapy-related toxic effects in patients with colorectal cancer. |
| Q30842757 | Prevention and treatment of chemotherapy- and radiotherapy-induced oral mucositis: a review |
| Q34346975 | Procedures for numerical analysis of circadian rhythms |
| Q35576191 | Progress in the medical treatment of advanced colorectal cancer |
| Q42318180 | Pronounced between-subject and circadian variability in thymidylate synthase and dihydropyrimidine dehydrogenase enzyme activity in human volunteers |
| Q37217358 | Prospective multicenter phase II clinical trial of FOLFIRI chemotherapy as a neoadjuvant treatment for colorectal cancer with multiple liver metastases |
| Q90301892 | Pulsatile Chemotherapeutic Delivery Profiles Using Magnetically Responsive Hydrogels |
| Q79846295 | Randomized trial of the efficacy of adjuvant chemotherapy for colon cancer with combination therapy incorporating the oral pyrimidine 1-hexylcarbamoyl-5-fluorouracil |
| Q52692013 | Relevance of a Mobile Internet Platform for Capturing Inter- and Intrasubject Variabilities in Circadian Coordination During Daily Routine: Pilot Study. |
| Q51817844 | Rescue chemotherapy using multidrug chronomodulated hepatic arterial infusion for patients with heavily pretreated metastatic colorectal cancer. |
| Q34551117 | Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival |
| Q73630379 | Resection of nonresectable liver metastases from colorectal cancer after percutaneous portal vein embolization |
| Q40510233 | Response rates of hepatic arterial infusion pump therapy in patients with metastatic colorectal cancer liver metastases refractory to all standard chemotherapies |
| Q34070317 | Risk factors determining chemotherapeutic toxicity in patients with advanced colorectal cancer |
| Q34335452 | Role of oxaliplatin combined with 5-fluorouracil and folinic acid in the first- and second-line treatment of advanced colorectal cancer. |
| Q73355992 | Schedule specific biochemical modulation of 5-fluorouracil in advanced colorectal cancer: a randomized study. GISCAD, IOR and collaborating centers |
| Q30238760 | Second-line systemic therapy for metastatic colorectal cancer. |
| Q43658212 | Second-line treatment with oxaliplatin + raltitrexed in patients with advanced colorectal cancer failing fluoropyrimidine/leucovorin-based chemotherapy |
| Q33400095 | Sequential FOLFOX-6 and gemcitabine for locally advanced and/or metastatic pancreatic cancer |
| Q36545850 | Severe anaphylactic reactions in patients receiving oxaliplatin therapy: a rare but potentially fatal complication |
| Q34897691 | Skin surface temperature rhythms as potential circadian biomarkers for personalized chronotherapeutics in cancer patients |
| Q28478419 | Strain- and sex-dependent circadian changes in abcc2 transporter expression: implications for irinotecan chronotolerance in mouse ileum |
| Q40135099 | Synergistic effect of triptolide combined with 5-fluorouracil on colon carcinoma |
| Q45107070 | Tacrolimus-induced neurotoxicity and nephrotoxicity is ameliorated by administration in the dark phase in rats |
| Q91928988 | Targeting the Canonical WNT/β-Catenin Pathway in Cancer Treatment Using Non-Steroidal Anti-Inflammatory Drugs |
| Q89565582 | The Role of the Body Clock in Asthma and COPD: Implication for Treatment |
| Q36957626 | The drug efficacy and adverse reactions in a mouse model of oral squamous cell carcinoma treated with oxaliplatin at different time points during a day |
| Q33389163 | The efficacy of a modified chronomodulated infusion of oxaliplatin, 5-fluorouracil and leucovorin in advanced colorectal cancer (preliminary data). |
| Q38097808 | The evolving role of oxaliplatin in the management of colorectal cancer. |
| Q34184090 | The relationship between fatigue and sleep in cancer patients: a review |
| Q36611554 | The role of haemoglobin level in predicting the response to first-line chemotherapy in advanced colorectal cancer patients |
| Q34805943 | The timing of introduction of pharmaceutical innovations in seven European countries |
| Q37241660 | Timing Matters: Circadian Rhythm in Sepsis, Obstructive Lung Disease, Obstructive Sleep Apnea, and Cancer |
| Q90642449 | Training the Circadian Clock, Clocking the Drugs, and Drugging the Clock to Prevent, Manage, and Treat Chronic Diseases |
| Q34351014 | Treatment of liver metastases from colorectal cancer: what is the best approach today? |
| Q34616010 | Treatment of liver metastases, an update on the possibilities and results |
| Q34328547 | Tumor chronobiology |
| Q28473259 | Tumor growth rate determines the timing of optimal chronomodulated treatment schedules |
| Q73214550 | Two-stage hepatectomy: A planned strategy to treat irresectable liver tumors |
| Q33865026 | Two-stage strategy for patients with extensive bilateral colorectal liver metastases. |
| Q64084632 | Ultrasonic Generation of Pulsatile and Sequential Therapeutic Delivery Profiles from Calcium-Crosslinked Alginate Hydrogels |
| Q92619821 | Understanding Quantitative Circadian Regulations Are Crucial Towards Advancing Chronotherapy |
| Q28077467 | WOMEN IN CANCER THEMATIC REVIEW: Circadian rhythmicity and the influence of 'clock' genes on prostate cancer |
| Q73878677 | [Current status of the treatment of hepatic metastases of colorectal carcinoma] |
| Q73642899 | [Toward the development of medical applications of chronobiology] |
Search more.